The aim of this document is to provide guidance on how to undertake a paediatric drug optimization exercise and identify key priority products for research and development. This guidance is for all WHO technical units undertaking a paediatric drug optimization exercise, all stakeholders involved in PADO processes as well as interested organizations and experts involved in the research and development of therapeutics in the public and private sectors.

Access the document